Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06211179 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT06211179 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 34 participants.
The verdict
NCT06211179, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study to assess the relative bioavailability of 5 mg Mavacamten opened capsule administered via nasogastric tube compared to intact oral 5 mg Mavacamten in healthy volunteers.
Interventions
- DRUG Treatment A: Mavacamten intact oral capsule
- DRUG Treatment B: Mavacamten open capsule in suspension
- DRUG Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2024-01-10 |
| Est. Completion | 2024-06-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06211179
The ClinicalTrials.gov registry entry for NCT06211179 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Treatment A: Mavacamten intact oral capsule is the first listed.
NCT06211179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06211179 about?
NCT06211179 is a clinical study titled "A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants". The purpose of this study to assess the relative bioavailability of 5 mg Mavacamten opened capsule administered via nasogastric tube compared to intact oral 5 mg Mavacamten in healthy volunteers.
What is the current status of trial NCT06211179?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2024-01-10. Estimated completion is 2024-06-13.
What interventions are being tested in trial NCT06211179?
The interventions under investigation include: Treatment A: Mavacamten intact oral capsule (DRUG), Treatment B: Mavacamten open capsule in suspension (DRUG), Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT) (DRUG).
Who is sponsoring clinical trial NCT06211179?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.